SIGA Technologies Inc (SIGA)

[chillswills37]

Right. Re:Monkeypox test "[P]atient given 200 mg of oral tecovirimat (TPOXX) twice daily for 2 weeks had no adverse effects and shed viral DNA for only 10 days. [...] The patient treated with tecovirimat had a shorter duration of symptoms and upper respiratory tract viral shedding than the other patients in the series.

[...] Treatment had to be stopped in three patients treated with 200 milligrams oral once-weekly brincidofovir following the development of elevated liver enzymes, indicating liver inflammation or injury. [...] 'Although optimum infection control and treatment strategies for this potentially dangerous pathogen are not established, our first-use data suggest brincidofovir has poor efficacy; however, prospective studies of tecovirimat in human monkeypox are warranted,' they wrote."
-----------------
UK: The smallpox drug tecovirimat could reduce symptoms and contagiousness, a study on antivirals in seven monkeypox patients has suggested. The study was published in The Lancet Infectious Diseases on May 24, 2022.

"It is the first report on in-hospital and household transmission of monkeypox outside of Africa," Hugh Adler, Liverpool School of Tropical Medicine, Liverpool, UK, and colleagues wrote in their study.

Human monkeypox is a zoonosis whose cause is monkeypox virus. It was reported first in central Africa in 1970 and has affected some of the poorest and most marginalised communities in the world. The clinical syndrome is characterised by rash, fever, and lymphadenopathy. Its complications include encephalitis, pneumonitis, secondary bacterial infections, and sight-threatening keratitis.
.
https://medicaldialogues.in/medicine/news/smallpox-drug-tecovirimat-may-reduce-duration-of-symptoms-and-infectivity-of-monkeypox-lancet-93525